Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets

Two fixed dose triple combination water-dispersible tablets produced by generic manufacturer Ranbaxy providing half- and quarter-doses of nevirapine, lamivudine and stavudine for paediatric use

Published
17 August 2006
By
Edwin J. Bernard
Acid-reducing agent increases saquinavir levels in HIV-negative volunteers

The stomach acid-reducing agent omeprazole (Losec) causes an 82% increase in the levels of saquinavir (Invirase) in the blood, when saquinavir is boosted with low-dose

Published
11 July 2006
By
Christopher Gadd
Conflicting pharmacokinetic results when lopinavir and atazanavir are double-boosted with ritonavir

The double boosted combination of twice-daily lopinavir/ritonavir (Kaletra) with once-daily atazanavir (Reyataz) may significantly increase or reduce Cmin (minimum) plasma lopinavir levels, according to conflicting

Published
06 June 2006
By
Edwin J. Bernard
HIV-positive children in UK and Ireland often given too low doses of antiretrovirals

A significant proportion of HIV-positive children in the United Kingdom and Ireland have been treated with suboptimal doses of antiretroviral drugs, according to a study

Published
19 May 2006
By
Michael Carter
HIV Pharmacology Workshop: Patch-testing to identify the genetic and clinical characteristics of abacavir hypersensitivity reaction - don’t try this at home

1. Clinical diagnosis of abacavir hypersensitivity reaction is imprecise. The clinical diagnosis of abacavir HSR syndrome is imprecise and hence using clinical diagnosis as the

Published
02 May 2006
By
Yasmin Halima
HIV Pharmacology Workshop: Explaining tenofovir renal toxicities and interactions with protease inhibitors

Interactions between tenofovir and protease inhibitors appear to be governed by a wider range of drug transporters than previously assumed, according to findings presented at

Published
02 May 2006
By
Yasmin Halima
HIV Pharmacology Workshop: Explaining the genetic basis of AZT toxicity

At this workshop more so than in previous years, there was an increasing emphasis on the impact of pharmaco-genetics, the intersection between host genetic influences

Published
02 May 2006
By
Yasmin Halima
HIV Pharmacology Workshop: The dangers of breaking up tablets for paediatric dosing

Further evidence that dividing adult Triomune tablets for use by children may result in under-dosing was presented last week at the HIV Pharmacology Workshop in

Published
01 May 2006
By
Yasmin Halima
HIV Pharmacology Workshop: Are drug levels affected by racial differences?

Racial differences in therapeutic responses have been reported previously in relation to efavirenz (Sustiva)- containing treatments in African-American patients (Haas D et al 2004) correlated

Published
01 May 2006
By
Yasmin Halima
Variation in gene linked to risk of resistance after stopping efavirenz treatment

Patients with a common genetic mutation are at an elevated risk of developing resistance to efavirenz (Sustiva) after stopping the drug, according to a study

Published
10 April 2006
By
Christopher Gadd

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.